The AAFP announced updated 2026 child/adolescent and adult immunization schedules, emphasizing that vaccines remain a safe, effective, and essential defense against preventable diseases. The revised schedules are intended to provide clear, practical, evidence-based guidance for physicians and clinicians.
Purpose of the Updates
The new schedules are designed to help clinicians navigate an expanding range of vaccine products by offering:
- Integration of newly available vaccines and options
- Clearer recommendations in complex or rapidly changing areas
- AAFP-specific clinical context and guidance
- Improved usability for everyday practice and patient conversations
Child and Adolescent Schedule Updates
Key changes include:
- Expanded and clarified guidance on meningococcal vaccines, including Penmenvy
- Updated recommendations for RSV monoclonal antibody (RSV-mAb) use
- Improved tables, clearer columns, revised notes language, and better differentiation between similar products
Adult Schedule Updates
Notable revisions include:
- Removal of PreHevbrio from listings
- Addition of Penmenvy with approved-use guidance
- Updated RSV notes and tables to support strong recommendations and patient discussions
Patient Education Resources
AAFP notes that familydoctor.org has refreshed patient materials covering:
- Protection from winter illnesses
- Cold and flu season prevention tips
- How vaccines work
How Recommendations Are Developed
AAFP states its schedules come from a rigorous internal review process involving:
- Analysis of CDC ACIP recommendations
- Review of U.S. Preventive Services Task Force guidance
- Evaluation of current scientific evidence and additional data sources
- Final approval by the AAFP Board of Directors
Ongoing Advocacy
The Academy continues to advocate for:
- Preservation of evidence-based vaccine recommendations
- Protection of ACIP’s independence and integrity
- Continued no-cost vaccine coverage for patients
